Please select a Capability in order to start your service request.
Fully-automated BD Phoenix™ CPO detect test helps detect dangerous pathogensSep 26, 2017
FRANKLIN LAKES, N.J., September 26, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenix™ automated microbiology system in Europe, the new BD Phoenix™ CPO detect test will help hospitals identify and contain infections caused by CPO, while potentially combating an increase in antimicrobial resistance (AMR).
According to the Centers for Disease Control and Prevention (CDC), CPOs, specifically carbapenem-resistant Enterobacteriaceae (CRE), represent a prominent AMR threat to public health because these dangerous microbes may be resistant to nearly all available antibiotics.2 These organisms are also on the World Health Organization (WHO) priority pathogen list as critical threats to public health.3 Reported rates of mortality associated with certain CPO infections vary widely from 22 to 72 percent.4 When CPOs are detected, rapid implementation of infection prevention measures are needed to prevent further transmission.
The BD Phoenix CPO detect test, included on BD Phoenix™ gram-negative panels, identifies CPOs and provides the Ambler classification of the enzyme produced. In contrast to conventional phenotypic methods for CPO detection that can take up to 96 hours, the BD Phoenix™ CPO detect test can detect CPOs accurately in under 36 hours.
The test allows hospitals and laboratories to categorize microbial resistance facilitating the rapid implementation of infection control procedures and the selection of appropriate antibiotics. It provides information that can be used to support hospitals in managing their antimicrobial stewardship programs more effectively.
“The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of capabilities is unmatched by all currently marketed tests,” said Kenneth S. Thomson, PhD, FIDSA, FAAM, FASM clinical professor of Pathology and Laboratory Medicine, University of Louisville School of Medicine. “It represents a significant advance in meeting an important clinical need.”
Fully integrated within BD Phoenix panels, the new BD Phoenix CPO detect test enables laboratories to offer a more comprehensive antimicrobial susceptibility test profile while improving laboratory process efficiency. The test is available in two configurations, offering flexibility to customers; a combo panel that detects the presence of CPOs, and the BD Phoenix™ emerge panel that detects the presence of CPOs and if positive, provides the Ambler classification of the carbapenemase.
“The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management,” said Steve Conly, vice president of Microbiology for BD. “Along with the BD Phoenix™ M50, this first-to-market phenotypic automated test to detect CPOs, expands BD’s portfolio of solutions for identification and antimicrobial susceptibility testing (ID/AST) and is another example of the company’s commitment to combating AMR.”
Visit bd.com/ds for more information.
About BD Phoenix™
The BD Phoenix™ automated identification and susceptibility testing system is part of BD’s line of products for rapid, accurate and reliable detection of microbial organisms. Using BD Phoenix products, laboratories can identify organisms and understand emerging antimicrobial resistance, improving communication with clinicians to improve both patient management and antibiotic stewardship.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.